Vanda Pharmaceuticals Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for VNDA, updated each market day.
VNDA AI Sentiment
AI sees no strong directional signal for Vanda Pharmaceuticals Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Sector
Exchange
Market Cap
$433,261,859
Cap Tier
Employees
533
Headquarters
WASHINGTON, DC
Listed Since
April 12, 2006
Website
VNDA Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
VNDA Volatility
Vanda Pharmaceuticals Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
